Phase I study of liposomal daunorubicin in relapsed and refractory acute myeloid leukemia

Oncology Reports

Volumn 10, Issue 4, 2003, Pages 915-920

  Bieker, Ralf ^a   Lerchenmüller, Christian ^a   Wehmeyer, Jürgen ^a   Serve, Hubert L ^a   Mesters, Rolf M ^a   Büchner, Thomas ^a   Berdel, Wolfgang E ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Acute myeloid leukemia; Anthracycline; Cardiotoxicity; Liposomal daunorubicin

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC; DAUNORUBICIN; LIPOSOME;

ACUTE DISEASE; AGED; ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; FEMALE; HUMAN; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MYELODYSPLASTIC SYNDROME; MYELOID LEUKEMIA; PHASE 1 CLINICAL TRIAL; SALVAGE THERAPY; TUMOR RECURRENCE;

ACUTE DISEASE; AGED; ANTIBIOTICS, ANTINEOPLASTIC; DAUNORUBICIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LEUKEMIA, MYELOID; LIPOSOMES; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEOPLASM RECURRENCE, LOCAL; SALVAGE THERAPY;

EID: 1542787544     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.10.4.915     Document Type: Article

References (27)

1. Yates J, Glidewell O, Wiernik P, Cooper MR, Steinberg D, Dosik H, Levy R, Hoagland C, Henry P, Gottlieb A, Cornell C, Berenberg J, Hutchison JL, Raich P, Nissen N, Ellison RR, Frelick R, James GW, Falkson G, Silver RT, Haurani F, Green M, Henderson E, Leone L and Holland JF: Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood 60: 454-462, 1982. (Pubitemid 12048693)
2. Büchner T, Urbanitz D, Hiddemann W, Rühl H, Ludwig WD, Fischer J, Aul HC, Vaupel HA, Kuse R and Zeile G: Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML cooperative group. J Clin Oncol 3: 1583-1589, 1985.
3. Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, Omura GA, Moore JO, Mclntyre OR and Frei E III: Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 331: 896-903, 1994. (Pubitemid 24299870)
4. Bishop JF, Matthews JP, Young GA, Szer J, Gillett A, Joshua D, Bradstock K, Enno A, Wolf MM, Fox R, Cobcroft R, Herrmann R, van Der Weyden M, Lowenthal RM, Page F, Garson OM and Juneja S: A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 87: 1710-1717, 1996. (Pubitemid 26068888)
5. Usui N, Dobashi N, Kobayashi T, Yano S, Maki N, Asai O, Saito T, Yamaguchi Y, Watanbe H, Kato A, Ogihara A, Katori M, Nagamine M, Takei Y, Yamazaki H, Funakoshi S, Tajima N, Ogawa M and Kuraishi Y: Role of daunorubicin in the induction therapy for adult acute myeloid leukemia. J Clin Oncol 16: 2086-2092, 1998. (Pubitemid 28265045)
6. Hewlett J, Kopecky KJ, Head D, Eyre HJ, Elias L, Kingsbury L, Balcerzak SP, Dabich L, Hynes H, Bickers JN and Appelbaum FR: A prospective evaluation of the roles of allogeneic marrow transplantation and low-dose monthly maintenance chemotherapy in the treatment of adult acute myelogenous leukemia (AML): a Southwest Oncology Group Study. Leukemia 9: 562-569, 1995.
7. Head D, Kopecky KJ, Weick J, Files JC, Ryan D, Foucar K, Montiel M, Bickers J, Fishleder A and Miller M: Effect of aggressive daunomycin therapy on survival in acute promyelocytic leukemia. Blood 86: 1717-1728, 1995.
8. Todeschini G, Meneghini V, Pizzolo G, Cassibba V, Ambrosetti A, Veneri D, Nadali G, Zanotti R, Tecchio C and Perona G: Relationship between Daunorubicin dosage delivered during induction therapy and outcome in adult acute lymphoblastic leukemia. Leukemia 8: 376-381, 1994. (Pubitemid 24096689)
9. Forssen EA, Coulter DM and Proffit RT: Selective in vivo localization of daunorubicin small unilamellar vesicles in solid tumours. Cancer Res 52: 3255-3261, 1992.
10. Forssen EA, Malé-Brune R, Adler-Moore JP, Lee MJA, Schmidt PG, Krasieva TB, Shimizu S and Tromberg BJ: Fluorescence imaging studies for the disposition of daunorubicin liposomes (DaunoXome®) within tumor tissue. Cancer Res 56: 2066-2075, 1996. (Pubitemid 26119909)
11. Forssen EA and Ross ME: DaunoXome® treatment of solid tumours: preclinical and clinical investigations. J Lip Res 4: 481-512, 1994. (Pubitemid 24130557)
12. Gill PS, Espina BM, Muggia F, Cabriales S, Tulpule A, Esplin JA, Liebman HA, Forssen E, Ross ME and Levine AM: Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin. J Clin Oncol 13: 996-1003, 1995.
13. Gill PS, Wernz J, Scadden DT, Cohen P, Mukwaya GM, von Roenn JH, Jacobs M, Kempin S, Silverberg I, Gonzales G, Rarick MU, Myers AM, Shepherd F, Sawka C, Pike MC and Ross ME: Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristin in AIDS-related Kaposi's sarcoma. J Clin Oncol 14: 2453-2364, 1996.
14. Richardson DS, Kelsey SM, Johnson SA, Tighe M, Cavenagh JD and Newland AC: Early evaluation of liposomal daunorubicin (DaunoXome®, NeXstar) in the treatment of relapsed and refractory lymphoma. Invest New Drugs 15: 247-253, 1997. (Pubitemid 27453879)
15. Yeo W, Chan KK, Mukwaya G, Ross M, Leung WT, Ho S, Chan AT and Johnson PJ: Phase II studies with DaunoXome in patients with nonresectable hepatocellular carcinoma: clinical and pharmacokinetic outcomes. Cancer Chemother Pharmacol 44: 124-130, 1999. (Pubitemid 29297058)
16. Cortes J, O'Brien S, Estey E, Giles F, Keating M and Kantarjian H: Phase I study of liposomal daunorubicin in patients with acute leukemia. Invest New Drugs 17: 81-87, 1999. (Pubitemid 29452751)
17. Fossa SD, Aass N and Paro G: A phase II study of DaunoXome in advanced urothelial transitional cell carcinoma. Eur J Cancer 34: 1131-1132, 1998. (Pubitemid 28308359)
18. Girard P-M, Bouchaud O, Goetschel A, Mukwaya G, Eestermans G, Ross M, Rozenbaum W and Saimot AG: Phase II study of liposomal encapsulated daunorubicin in the treatment of AIDS-associated mucocutaneous Kaposi's sarcoma. AIDS 10: 753-757, 1996. (Pubitemid 26172778)
19. Pratt G, Wiles ME, Rawstron AC, Davies FE, Fenton JA, Proffitt JA, Child JA, Smith GM and Morgan GJ: Liposomal daunorubicin: in vitro and in vivo efficacy in multiple myeloma Hematol Oncol 16: 47-55, 1998. (Pubitemid 29083321)
20. Guerci A, Merlin JL, Missoum N, Feldmann L, Marchal S, Witz F, Rose C and Guerci O: Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry. Blood 85: 2147-2153, 1995.
21. Leith CP, Kopecky KJ, Godwin J, McConnell T, Slovak ML, Chen I, Head DR, Appelbaum FR and Willman CL: Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to dtandard chemotherapy. A Southwest Oncology Group Study. Blood 89: 3323-3329, 1997.
22. Berry G, Billingham M, Alderman E, Richardson P, Torti F, Lum B, Patek A and Martin FJ: The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin. Ann Oncol 9: 711-716, 1998. (Pubitemid 28394155)
23. Billingham M and Bristow M: Evaluation of anthracycline cardiotoxicity: predictive ability and functional correlation of endomyocardial biopsy. Cancer Treat Symp 3: 71-76, 1984. (Pubitemid 15191720)
24. Treat J, Greenspan A, Forst D, Sanchez JA, Ferrans VJ, Potkul LA, Woolley PV and Rahman A: Antitumor activity of liposome-encapsulated doxorubicin in advanced breast cancer: phase II study. J Natl Cancer Inst 82: 1706-1710, 1990.
25. List AF, Spier C, Greer J, Wolff S, Hutter J, Dorr R, Salmon S, Futscher B, Baier M and Dalton W: Phase I/II trial of cyclosporine A as a chemotherapy-resistance modifier in acute leukemia. J Clin Oncol 11: 1652-1659, 1993.
26. Verdonck LF, Lokhorst HM, Roovers DJ and van Heugten HG: Multidrug-resistant acute leukemia cells are responsive to prolonged exposure of daunorubicin: implications for liposome-encapsulated daunorubicin. Leukemia Res 22: 249-256, 1998. (Pubitemid 28224662)
27. Michieli M, Damiani D, Ermacora A, Masolini P, Michelutti A, Michelutti T, Russo D, Pea F and Baccarani M: Liposome-encapsulated daunorubicin for PGP-related multidrug resistance. Br J Haematol 106: 92-99, 1999. (Pubitemid 29343532)